CoChat
Sign Up
Cited by 21Hepatitis C virus researchVirus-based gene therapy researchAnimal Virus Infections Studies

Induction of Broadly Neutralising HCV Antibodies in Mice by Integration-Deficient Lentiviral Vector-Based Pseudotyped Particles

Open access
Deng, Yao, Guan, Jie, Wen, Bo, Zhu, Na, Chen, Hong, Song, Jindong, Yang, Yang, Wang, Yue +1 more·2013·PLoS ONE
DOI 10.1371/journal.pone.0062684PMC PMC3633868
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Integration-deficient lentiviral vectors (IDLVs) are a promising platform for immunisation to elicit both humoral immunity and cellular mediated immunity (CMI). Here, we compared the specific immunity in mice immunised via different regimens (homologous and cocktail) with IDLV-based HCV pseudoparticles (HCVpps) carrying pseudotyped glycoproteins E1E2 and bearing the HCV NS3 gene. Humoral and cell-mediated immune responses were also evaluated after IDLV-HCVpp immunisation combined with heterologous rAd5-CE1E2 priming protocols. Sera from the mice effectively elicited anti-E1, -E2, and -NS3 antibody responses, and neutralised various HCVpp subtypes (1a, 1b, 2a, 3a and 5a). No significant CMI was detected in the groups immunised with IDLV-based HCVpps. In contrast, the combination of rAd5-CE1E2 priming and IDLV-based HCVpp boosting induced significant CMI against multiple antigens (E1, E2, and NS3). CONCLUSION: IDLV-based HCVpps are a promising vaccination platform and the combination of rAd5-CE1E2 and IDLV-based HCVpp prime-boost strategy should be further explored for the development of a cross-protective HCV vaccine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0062684

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Vaccinia virus, Zika virus, and human cytomegalovirus have been investigated in pre-clinical studies to test immune responses.

    “Vaccinia virus [81], Zika virus [82], and human cytomegalovirus [83] have also been investigated in pre-clinical studies to test their immune responses.”

    From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [83]

    For the vaccinia-virus portion of the sentence, the cited paper reports a preclinical mouse study of an HCV lentiviral-vector vaccine, not a vaccinia-virus study (Discussion; Immunisation of Mice, page unavailable). Vaccinia appears only in a References entry naming Deng et al. (2009) as the study of a vaccinia-virus prime-boost regimen in mice. The Zika and human-cytomegalovirus portions have separate citations and are not judged here. (LLM, conf=0.84) It matches “A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice” (2009) instead.

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. [1]Strickland GT, El-Kamary SS, Klenerman P, Nicosia A (2008) Hepatitis C vaccine: supply and demand. Lancet Infect Dis 8: 379– 386. 18501853
  2. [2]Shimakami T, Lanford RE, Lemon SM (2009) Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol. 9(5): 537– 44. PMC2782474 19762279
  3. [3]Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol. 25: 71– 99. 17067278
  4. [4]Halliday J, Klenerman P, Barnes E (2011) Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10(5): 659– 72. 21604986 PMC3112461
  5. [5]Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263– 267. 8602510
  6. [6]Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, et al (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873– 9880. 9811723 PMC110499
  7. [8]Hu B, Tai A, Wang P (2011) Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev. 239(1): 45– 61. PMC3030993 21198664
  8. [9]Arce F, Rowe HM, Chain B, Lopes L, Collins MK (2009) Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther 17: 1643– 1650. 19584812 PMC2835272
  9. [11]Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, et al (2004) Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101: 7705– 7710. 15136748 PMC419670
  10. [12]Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U SA. 104: 6025– 6030. PMC1851610 17392433
  11. [13]Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, et al (2010) Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus re-infection in liver transplantation. J Exp Med 207: 2019– 2031. 20713596 PMC2931157
  12. [14]Puig M, Major ME, Mihalik K, Feinstone SM (2004) Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22 (8): 991– 1000. 15161076
  13. [15]Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14(1): 25– 27. 18064037
  14. [16]Kuiken C, Simmonds P (2009) Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510, 33–53. 19009252
  15. [17]Roy P, Noad R (2009) Virus-like particles as a vaccine delivery system: Myths and facts. Adv. Exp. Med. Biol. 655, 145–158. PMC7124136 20047040
  16. [18]Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197: 633– 642. 12615904 PMC2193821
  17. [19]Zhang K, Tan W, Deng Y, Li J, Wu X, et al (2008) Development of Infectious Pseudo-particle Harboring Three Subtypes Hepatitis C Virus Glycoproteins and Their Application in Neutralization Assays. Chinese Journal of Virology 24(4): 288– 294. 18780632
  18. [20]Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, et al. (2005) Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41, 265–274. 15660396
  19. [21]Guan J, Wen B, Deng Y, Zhang K, Chen H, et al (2011) Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J. 8(1): 506. PMC3225406 22054309
  20. [22]Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio Tet al (1995) Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346: 1006– 1007. 7475549
  21. [23]Leavitt AD, Shiue L, Varmus HE (1993) Site-directed Mutagenesis of HIV- 1 Integrase Demonstrates Differential Effects on Integrase Functions in Vitro. J Bio Chem. 288(3)2113–9. 8420982
  22. [24]Wen B, Deng Y, Guan J, Yan W, Wang Y, et al (2011) Signal peptide replacements enhance expression and secretion of hepatitis C virus envelope glycoproteins. Acta Biochim Biophys Sin 43 (2): 96– 102. 21196448
  23. [25]Dreux M, Cosset FL (2009) Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp). Methods Mol. Biol. 510, 427–438. 19009280
  24. [26]Bian T, Zhou Y, Bi S, Tan W, Wang Y (2009) HCV envelope protein function is dependent on the peptides preceding the glycoproteins. Biochem Biophys Res Commun. 2 378(1): 118– 22. 19013428
  25. [27]Deng Y, Zhang K, Tan W, Wang Y, Chen H, et al (2009) A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice. Vaccine 27: 2085– 2088. 19356609 PMC7115398
  26. [28]Qi X, Gao Y, Lu R, Deng Y, Meng X, et al. (2011) Peptide Mapping of H-2d Restricted T-cell Epitope against Six Antigens of HIV-1 Subtype B’/C by ELISPOT Assay. Chinese Journal of Virology 27(1) 34–43. 21462504
  27. [29]Negri DR, Michelini Z, Bona R, Blasi M, Filati P, et al (2011) Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther. 11(6): 739– 50. 21434847
  28. [30]Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, et al (2003) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100: 14199– 14204. 14617769 PMC283569
  29. [31]Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, et al (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101: 10149– 10154. 15220475 PMC454180
  30. [32]Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, et al (2005) Evidence for cross-genotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102: 4560– 4565. 15767578 PMC555507
  31. [33]Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U SA. 104: 6025– 6030. PMC1851610 17392433
  32. [34]Houghton M (2011) Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev. 239(1): 99– 108. 21198667
  33. [35]Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, et al. (2007) Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25, 7773–7784. 17919789
  34. [36]Lin Y, Kwon T, Polo J, Zhu YF, Coates S, et al. (2008) Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J. Virol. 82, 7492–7503. PMC2493334 18508900
  35. [37]Frey SE, Houghton M, Coates S, Abrignani S, Chien D, et al (2010) Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 28(38): 6367– 73. PMC2923449 20619382
  36. [38]Ray R, Meyer K, Banerjee A, Basu A, Coates S, et al. (2010) Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 202, 862–866. PMC2931414 20677942
  37. [39]Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, et al (2007) Immunization with hepatitits C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 104: 8427– 8432. 17485666 PMC1895966
  38. [40]Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, et al (2006) A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12: 190– 197. 16462801
  39. [41]Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, et al. (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3, 94ra71. 21813755
  40. [42]Coutant F, Frenkiel MP, Despres P, Charneau P (2008) Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One. 3(12): e3973. PMC2600612 19096527
  41. [43]Karwacz K, Mukherjee S, Apolonia L, Blundell MP, Bouma G, et al (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83: 3094– 103. 19176629 PMC2655594
  42. [45]Hu B, Dai B, Wang P (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28: 6675– 83. 20709004 PMC2956406

Cited by

Sorted by citations

Authors
Deng, Y., Guan, J., Wen, B., Zhu, N., Chen, H., Song, J., Yang, Y., Wang, Y., & Tan, W.
Affiliations
Chinese Center For Disease Control and Prevention (CN)
Corresponding author
  • Wang, Yue
  • Tan, Wenjie
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-04-23
Volume
8
Issue
4
Pages
e62684
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0062684
PMC
PMC3633868
OpenAlex
W2079496848
Cited by
21
References
3
Citations by year
2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2016: 2 · 2015: 5 · 2014: 3
FWCI
2.08
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Genentech
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
hepatitis C virus, broadly neutralizing antibodies, HCV NS3, heterologous prime-boost, humoral immunity, cell-mediated immunity, cross-protective vaccine, HCV vaccine development
MeSH terms
Adenoviridae, Animals, Cell Line, Female, Genetic Vectors, Humans, Immunoglobulin G, Immunization, Virion, Lentivirus, Hepacivirus, Virus Integration, Hepatitis C Antibodies, Gene Order, Mice, Immunity, Humoral, Cross Protection, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review